Why treatments do(n't) work in vitiligo: An autoinflammatory perspective

Autoimmunity Reviews

Volumn 14, Issue 4, 2015, Pages 332-340

  Speeckaert, Reinhart ^a   Speeckaert, Marijn M ^a   van Geel, Nanja ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Autoinflammatory; Pathogenesis; Treatment; Vitiligo

Indexed keywords

AFAMELANOTIDE; AZATHIOPRINE; CYCLOSPORIN; HYDROXYCHLOROQUINE; INFLAMMASOME; METHOTREXATE; NEUROPEPTIDE; PIMECROLIMUS; TACROLIMUS; CALCINEURIN INHIBITOR; GLUCOCORTICOID; HEAT SHOCK PROTEIN 70; TUMOR NECROSIS FACTOR ALPHA;

AUTOINFLAMMATORY DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; KERATINOCYTE; MELANOCYTE; OXIDATIVE STRESS; PATHOGENESIS; PUVA; REGULATORY T LYMPHOCYTE; REVIEW; TARGET CELL; TH17 CELL; ULTRAVIOLET B RADIATION; VITILIGO; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; PHOTOTHERAPY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CALCINEURIN INHIBITORS; GLUCOCORTICOIDS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KERATINOCYTES; MELANOCYTES; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET THERAPY; VITILIGO;

EID: 84923079564     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.003     Document Type: Review

References (76)

1. Abu Tahir M., Pramod K., Ansari S.H., Ali J. Current remedies for vitiligo. Autoimmun Rev 2010, 9:516-520.
2. Hedley S.J., Metcalfe R., Gawkrodger D.J., Weetman A.P., Mac Neil S. Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules. Br J Dermatol 1998, 139:965-973.
3. Gauthier Y., Cario Andre M., Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?. Pigment Cell Res 2003, 16:322-332.
4. Kumar R., Parsad D., Kanwar A.J. Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo. Br J Dermatol 2011, 164:187-191.
5. Reichert-Faria A., Jung J.E., Neto V.M., de Castro C.C., Mira M.T., Noronha L. Reduced immunohistochemical expression of Discoidin Domain Receptor 1 (DDR1) in vitiligo skin. J Eur Acad Dermatol Venereol 2013, 27:1057-1079.
6. Mosenson J.A., Flood K., Klarquist J., Eby J.M., Koshoffer A., Boissy R.E., et al. Preferential secretion of inducible HPS70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res 2014, 27:209-220.
7. Mosenson J.A., Eby J.M., Hernandez C., Le Poole I.C. A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol 2013, 22:566-569.
8. Yu R., Broady R., Huang Y., Wang Y., Yu J., Gao M., et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One 2012, 7:e51040.
9. Jimbow K., Chen H., Park J.S., Thomas P.D. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 2001, 144:55-65.
10. Van den Broon J.G., Konijnenberg D., Dellemijn T.A., van der Veen J.P., Bos J.D., Melief C.J., et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009, 129:2220-2232.
11. Seleit I., Bakry O.A., Abdou A.G., Dawoud N.M. Immunohistochemical expression of aberrant Notch-1 signalling in vitiligo: an implication for pathogenesis. Ann Diagn Pathol 2014, 18:117-124.
12. Lee A.Y. Role of keratinocytes in the development of vitiligo. Ann Dermatol 2012, 24:115-125.
13. Marie J., Kovacs D., Pain C., Jouary T., Cota C., Vergier B., et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol 2014, 170:816-823.
14. Lan C.C., Chen G.S., Chiou M.H., Wu C.S., Chang C.H., Yu H.S. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus induces repigmentation in patient with vitiligo. Br J Dermatol 2005, 153:498-505.
15. Wu C.S., Yu C.L., Wu C.S., Lan C.C., Yu H.S. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 2004, 13:755-763.
16. Kawakami T., Ohgushi A., Hirobe T., Soma Y. Effects of 1,25-dihydroxyvitamin D3 on human epidermal melanocytes and melanoblasts. J Dermatol Sci 2014, 76:72-74.
17. Lim H.W., Grimes P.E., Agbai O., Hamzavi I., Henderson M., Haddican M., et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 2014, 10.1001/jamadermatol.2014.1875.
18. Kapoo R., Phiske M.M., Jerajani H.R. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol 2009, 160:861-863.
19. Joo K., Park W., Kwon S.R., Lim M.J., Jung K.H. Improvement of vitiligo in a patient with rheumatoid arthritis after hydroxychloroquine treatment. Int J Rheum Dis 2014, 10.1111/1756-185X.12442.
20. Taïeb A., Seneschal J. Targeting iHSP70 in vitiligo: a critical step for cure?. Exp Dermatol 2013, 22:570-577.
21. Van Herwijnen M.J., Van Der Zee R., Van Eden W., Broere F. Heat shock proteins can be targets of regulatory T cells for therapeutic intervention in rheumatoid arthritis. Int J Hyperthermia 2013, 29:448-454.
22. Maresca V., Roccella M., Roccella F., Camera E., Del Porto G., Passi S., et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997, 109:310-313.
23. Westerhof W., d'Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res 2007, 20:345-359.
24. Jian Z., Li K., Song P., Zhu G., Zhu L., Cui T., et al. Impaired activation of the Nrf2-ARE signalling pathway undermines H2O2-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo. J Invest Dermatol 2014, 134:2221-2230.
25. Colucci R., Böhm M., Moretti S. Commentary from the editorial board to vitiligo: interplay between oxidative stress and immune system (Laddha et al.). Exp Dermatol 2013, 22:397-398.
26. Richmond J.M., Frisoli M.L., Harris J.E. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol 2013, 25:676-682.
27. Chen G., Shaw M.H., Kim Y.G., Nuñez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009, 4:365-398.
28. Karsli N., Akcali Ozgoztasi O., Kirtak N., Inaloz S. Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy. J Int Med Res 2014, 42:799-805.
29. Lubaki L.J., Ghanem G., Vereecken P., Fouty E., Benammar L., Vadoud-Seyedi J., et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Arch Dermatol Res 2010, 302:131-137.
30. Song X., Mosby N., Yang J., Xu A., Abdel-Malek Z., Kadekaro A.L. Alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res 2009, 22:809-818.
31. Kadkaro Al, Chen J., Yang J., Chen S., Jameson J., Swope V.B., et al. Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signalling pathway in human melanocytes. Mol Cancer Res 2012, 10:778-786.
32. Kokot A., Metze D., Mouchet N., Galibert M.D., Schiller M., Luger T.A., et al. Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2-dependent gene expression in human skin. Endocrinology 2009, 150:3197-3206.
33. Karsli N., Akcali C., Ozgoztasi O., Kirtak N., Inaloz S. Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy. J Int Med Res 2014, 42:799-805.
34. Elgoweini M., Nour El Din N. Response of vitiligo to narrowband ultraviolet B and oral antioxidants. J Clin Pharmacol 2009, 49:825-855.
35. Parsad D., Pandhi R., Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 2003, 28:285-287.
36. Franchi L., Eigenbrod T., Muñoz-Planillo R., Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009, 10:241-247.
37. Levandowski C.B., Mailloux C.M., Ferrara T.M., Gowan K., Ben S., Jin Y., et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A 2013, 110:2952-2956.
38. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10:89-102.
39. Dinarello C.A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013, 25:469-484.
40. Laddha N.C., Dwivedi M., Mansuri M.S., Singh M., Patel H.H., Agarwal N., et al. Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility. PLoS One 2014, 15:e107020.
41. van Geel N.A., Mollet I.G., De Schepper S., Tjin E.P., Vermaelen K., Clark R.A., et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010, 23:375-384.
42. van den Boorn J.G., Konijnenberg D., Dellemijn T.A., van der Veen J.P., Bos J.D., Melief C.J., et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009, 129:2220-2232.
43. Oyarbide-Valencia K., van den Boorn J.G., Denman C.J., Li M., Carlson J.M., Hernandez C., et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 2006, 5:486-492.
44. Byrne K.T., Turk M.J. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2011, 2:684-694.
45. Mahmoud F., Abul H., al-Saleh Q., Haines D., Burleson J., Morgan Gl Peripheral T-cell activation in non-segmental vitiligo. J Dermatol 1998, 25:637-640.
46. Greco A., Fusconi M., Gallo A., Turchetta R., Marinelli C., Macri G.F., et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 2013, 12:1033-1038.
47. Garcia-Melendez M.E., Salinas-Santander M., Sanchez-Dominguez C., Gonzalez-Cardenas H., Cerda-Flores R.M., Ocampo-Candiani J., et al. Protein tyrosinase phosphatase PTPN22+ 1858C/T polymorphism is associated with active vitiligo. Exp Ther Med 2014, 8:1433-1437.
48. Klarquist J., Cecele J.D., Hernandez C., Wainwright D.A., Strickland F.M., Overbeck A., et al. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010, 23:276-286.
49. Lili Y., Yi W., Ji Y., Yue S., Weimin S., Ming L. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012, 7:e37513.
50. Dwivedi M., Laddha N.C., Imran M., Shah B.J., Begum R. Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Pigment Cell Melanoma Res 2011, 24:737-740.
51. Elela M.A., Hegazy R.A., Fawzy M.M., Rashed L.A., Rasheed H. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case-controlled study on eighty-four patients. Eur J Dermatol 2013, 23:350-355.
52. Kotobuki Y., Tanemura A., Yang L., Itoi S., Wataya-Kaneda M., Murota H., et al. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res 2012, 25:219-230.
53. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1β and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
54. Hegazy R.A., Fawzy M.M., Gawdag H.I., Samir N., Rashed L.A. T helper 17 and Tregs: a novel proposed mechanism for NB-UVB in vitiligo. Exp Dermatol 2014, 23:283-286.
55. van Geel N., Speeckaert R., Mollet I., De Schepper S., De Wolf J., Tjin E.P., et al. In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res 2012, 25:57-65.
56. Simon D., Vassina E., Yousefi S., Kozlowski E., Braathen L.F., Simon H.U. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004, 114:887-895.
57. Hoetzenecker W., Ecker R., Kopp T., Stuetz A., Stingl G., Elbe-Bürger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005, 115:1276-1283.
58. Rana S., Rogers L.J., Halliday G.M. Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am J Pathol 2011, 178:2783-2791.
59. Moftah N.H., El-Barbary A., Ismail M.A., Ali N.A. Effect of narrow band-ultraviolet B on CD4(+) CD25(high) FoxP3(+) T-lymphocytes in the peripheral blood of vitiligo patients. Photodermatol Photoimmunol Photomed 2014, 30:254-261.
60. Gupta A.K., Ellis C.N., Nickoloff B.J., Goldfarb M.T., Ho V.C., Rocher L.L., et al. Oral cyclosporin in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990, 126:339-350.
61. Alghamdi K., Khurrum H. Methotrexate for the treatment of generalized vitiligo. Saudi Pharm J 2013, 21:423-424.
62. Radmanesh M., Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 2006, 17:151-153.
63. Aydingõz I.E., Kanmaz-Özer M., Gedikbasi A., Vural P., Doğru-Abbasoğlu S., Uysal M. The combination of tumour necrosis factor-alpha-308A and interleukin-10-1082G gene polymorphisms and increased serum levels of related cytokines: susceptibility to vitiligo. Clin Exp Dermatol 2014, 10.1111/ced.12446.
64. Fiorino G., Danese S., Pariente B., Allez M. Paradoxal immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev 2014, 13:15-19.
65. Bassiouny D.A., Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2011, 36:292-297.
66. Chatterjee S., Eby J.M., Al-Khami A.A., Soloshchenko M., Kang H.K., Kaur N., et al. A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol 2014, 134:1285-1294.
67. Dwivedi M., Kemp E.H., Laddha N.C., Mansuri M.S., Weetman A.P., Begum R. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. Autoimmun Rev 2015, 14:49-56.
68. Waterman E.A., Gawkrodger D.J., Watson P.F., Weetman A.P., Kemp E.H. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. J Invest Dermatol 2010, 130:230-240.
69. Sandoval-Cruz M., García-Carrasco M., Sánchez-Porras R., Mendoza-Pinto C., Jiménez-Hernández M., Munguía-Realpozo P., et al. Immunopathogenesis of vitiligo. Autoimmun Rev 2011, 10:762-765.
70. Ruiz-Argüelles A., García-Carrasco M., Jimenez-Brito G., Sánchez-Sosa S., Pérez-Romano B., Garcés-Eisele J., et al. Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol 2013, 174:229-236.
71. Kroon M.W., Kemp E.H., Wind B.S., Krebbers G., Bos J.D., Gawkrodger D.J., et al. Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. J Eur Acad Dermatol Venereol 2013, 27:1172-1175.
72. Teulings H.E., Willemsen K.J., Glykotridis I., Krebbers G., Komen L., Kroon M.W., et al. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo. Pigment Cell Melanoma Res 2014, 27:1086-1096.
73. Colucci R., Lotti F., Dragoni F., Arunachalam M., Lotti T., Benvenga S., et al. High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients. Br J Dermatol 2014, 171:786-798.
74. Sanchez-Sosa S., Aguirre-Lombardo M., Jimenez-Brito G., Ruiz-Argüelles A. Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo. Clin Exp Immunol 2013, 173:179-183.
75. Bertolotti A., Boniface K., Vergier B., Mossalayi D., Taieb A., Ezzedine K., et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res 2014, 27:398-407.
76. Heier I., Søyland E., Krogstad A.L., Rodríguez-Gallego C., Nenseter M.S., Jahnsen F.L. Sun exposure rapidly reduces plasmacytoid dendritic cells and inflammatory dermal dendritic cells in psoriatic skin. Br J Dermatol 2011, 165:792-801.